ABT

Abbott Laboratories
D

ABT

Arincen83/100B

Abbott Laboratories cash on hand 1985–2026

Abbott Laboratories had 5.60B USD in cash and short-term investments on 30 June 2026, down 23.1% on a year before. At the end of fiscal year 2025 it had 8.94B USD.

Last updated 3 Nov 2026 · Next report 28 Jan 2027

Cash on hand

Growth

Fiscal yearPeriod endingCash on handGrowthTotal debtNet cash
Latest quarter30 Jun 20265.60B-23.06%32.61B-27.01B
FY202531 Dec 20258.94B+12.20%15.07B-6.13B
FY202431 Dec 20247.97B+9.45%15.28B-7.31B
FY202331 Dec 20237.28B-28.43%15.87B-8.59B
FY202231 Dec 202210.17B-0.77%17.95B-7.78B
FY202131 Dec 202110.25B+43.38%19.25B-9.00B
FY202031 Dec 20207.15B+72.66%19.89B-12.74B
FY201931 Dec 20194.14B+1.32%19.10B-14.96B
FY201831 Dec 20184.09B-57.48%19.57B-15.48B
FY201731 Dec 20179.61B-48.81%27.92B-18.31B
FY201631 Dec 201618.78B+206.53%22.01B-3.23B
FY201531 Dec 20156.13B+37.33%9.00B-2.88B
FY201431 Dec 20144.46B-44.92%7.83B-3.37B
FY201331 Dec 20138.10B-46.63%6.56B1.54B
FY201231 Dec 201215.17B+87.39%20.48B-5.30B
FY201131 Dec 20118.10B+10.56%15.41B-7.32B
FY201031 Dec 20107.32B-26.26%18.92B-11.59B
FY200931 Dec 20099.93B+95.53%16.46B-6.52B
FY200831 Dec 20085.08B+80.08%11.45B-6.37B
FY200731 Dec 20072.82B+105.38%12.21B-9.39B
FY200631 Dec 20061.37B-53.54%12.41B-11.04B
FY200531 Dec 20052.96B+43.57%6.63B-3.68B
FY200431 Dec 20042.06B+60.05%6.78B-4.72B
FY200331 Dec 20031.29B+33.15%5.99B-4.70B
FY200231 Dec 2002966.13M+35.40%6.42B-5.46B
FY200131 Dec 2001713.54M-38.31%7.29B-6.58B
FY200031 Dec 20001.16B+59.92%1.56B-399.10M
FY199931 Dec 1999723.30M+88.69%2.23B-1.51B
FY199831 Dec 1998383.32M+47.99%3.10B-2.72B
FY199731 Dec 1997259.01M+110.43%2.72B-2.46B
FY199631 Dec 1996123.08M-61.01%2.32B-2.19B
FY199531 Dec 1995315.70M+0.12%1.49B-1.17B
FY199431 Dec 1994315.33M-16.76%1.06B-744.27M
FY199331 Dec 1993378.83M+224.89%1.15B-771.61M
FY199231 Dec 1992116.60M+93.05%1.03B-909.70M
FY199131 Dec 199160.40M+77.65%669.40M-609.00M
FY199031 Dec 199034.00M+150.00%798.60M-764.60M
FY198931 Dec 198913.60M-97.67%447.20M-433.60M
FY198831 Dec 1988582.60M+12.06%842.60M-260.00M
FY198731 Dec 1987519.90M+7.95%877.40M-357.50M
FY198631 Dec 1986481.60M+10.08%889.10M-407.50M
FY198531 Dec 1985437.50M—565.90M-128.40M

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Total debt,Free cash flow,Stock buybacks,Balance sheet

Common questions about Abbott Laboratories's cash

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.